Debbie Rigby rounds up the latest in research news
A prospective analysis over 200,000 participants shows an association between regular use of PPIs and the risk of type 2 diabetes. Regular PPI users had a 24% higher risk of diabetes than non-users. The absolute risk of diabetes among regular PPI users was 7.44/1000 person-years compared with 4.32/1000 person-years among non-users. The risk of diabetes increased with duration of PPI use. The NNH for regular PPI users was 319 over 1 year, 171 over 2 years and 77 over 5 years.
In contrast to the previous study, a systematic review and meta-analysis of 7 studies showed no increased risk of incident diabetes with PPI use. PPIs were associated with a significant decrease in HbA1c and fasting blood glucose in patients with diabetes compared to patients treated with standard therapy without PPI use.
Journal of Clinical Endocrinology & Metabolism, 2021.
This systematic review of 24 studies suggests community-based pharmacists can lead deprescribing interventions and that they are valuable partners in deprescribing collaborations, providing necessary monitoring throughout tapering and post-follow-up to ensure the success of an intervention. Medication review by community-based pharmacist can lead to successful deprescribing of high-risk medications.
British Journal of Clinical Pharmacology, first published 21 June 2021.
A network meta-analysis of RCTs and real-world data shows that topical NSAIDs are more effective than paracetamol but not oral NSAIDs for function improvement in people with knee osteoarthritis. Topical NSAIDs are safer than paracetamol or oral NSAIDs in trials and real-world data. Topical NSAIDs had a lower risk of gastrointestinal adverse effects than paracetamol and oral NSAIDs. In real-world data, topical NSAIDs showed lower risks of all-cause mortality, cardiovascular diseases and gastrointestinal bleeding than paracetamol during a one-year follow-up.
Osteoarthritis and Cartilage, published 23 June 2021.